Back to top

Why the Earnings Streak Will Continue for Magellan Health (MGLN)

Read MoreHide Full Article

Looking for a stock that might be in a good position to beat earnings at its next report? Consider Magellan Health, Inc. (MGLN - Free Report) , a firm in the Medical - HMOs industry, which could be a great candidate for another beat.

This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. In fact, in these reports, MGLN has beaten estimates by at least 10% in both cases, suggesting it has a nice short-term history of crushing expectations.

Earnings in Focus

Two quarters ago, MGLN expected to post earnings of $1.42 per share, while it actually produced $1.64 per share, a beat of 15.5%. Meanwhile, for the most recent quarter, the company looked to deliver earnings of $2.29 per share, when it actually reported earnings of $2.55 per share instead, representing a 11.3% positive surprise.

Magellan Health, Inc. Price and EPS Surprise

Thanks in part to this history, recent estimates have been moving higher for Magellan Health. In fact, the Earnings ESP for MGLN is positive, which is a great sign of a coming beat.

After all, the Zacks Earnings ESP compares the most accurate estimate to the broad consensus, looking to find stocks that have seen big revisions as of late, suggesting that analysts have recently become more bullish on the company’s earnings prospects. This is the case for MGLN, as the firm currently has a Zacks Earnings ESP of 2.54%, so another beat could be around the corner.

This is particularly true when you consider that MGLN has a great Zacks Rank #2 (Buy) which can be a harbinger of outperformance and a signal for a strong earnings profile. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

When you add this solid Zacks Rank to a positive Earnings ESP, a positive earnings surprise happens nearly 70% of the time, so it seems pretty likely that MGLN could see another beat at its next report, especially if recent trends are any guide.

Zacks Editor-in-Chief Goes "All In" on This Stock

Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.

Download it free >>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Magellan Health, Inc. (MGLN) - free report >>

More from Zacks Tale of the Tape

You May Like